Lynparza receives approval in Japan for the treatment of advanced ovarian cancer
Lynparza receives approval in Japan for the treatment of advanced ovarian cancer
Results 1 – 10 of 158 for LYNPARZA (0.02 seconds)
Lynparza receives positive EU CHMP opinion in platinum-sensitive relapsed ovarian cancer
Lynparza receives positive EU CHMP opinion in platinum-sensitive relapsed ovarian cancer
Lynparza approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers
Lynparza approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers
Lynparza recommended for approval in the EU by CHMP for BRCA-mutated metastatic castration-resistant prostate cancer
Lynparza recommended for approval in the EU by CHMP for BRCA-mutated metastatic castration-resistant prostate cancer
Lynparza improved median time patients lived without disease progression to over four and half years in BRCA-mutated advanced ovarian cancer vs. just over one year with placebo
Lynparza improved median time patients lived without disease progression to over four and half years in BRCA-mutated advanced ovarian cancer vs. just ...
Lynparza demonstrated overall survival benefit in Phase III PROfound trial for BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer
Lynparza demonstrated overall survival benefit in Phase III PROfound trial for BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer
Lynparza receives additional and broad approval in the US for ovarian cancer
Lynparza receives additional and broad approval in the US for ovarian cancer
Lynparza significantly delays disease progression in Phase III 1st-line SOLO-1 trial for ovarian cancer
Lynparza significantly delays disease progression in Phase III 1st-line SOLO-1 trial for ovarian cancer
Lynparza receives approval in Japan for the treatment of advanced ovarian cancer
Lynparza receives approval in Japan for the treatment of advanced ovarian cancer
Lynparza receives positive EU CHMP opinion in platinum-sensitive relapsed ovarian cancer
Lynparza receives positive EU CHMP opinion in platinum-sensitive relapsed ovarian cancer